Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

ChrisInSF, I agree with you and Dan.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
couldbebetter Member Profile
 
Followed By 18
Posts 3,064
Boards Moderated 1
Alias Born 10/20/14
160x600 placeholder
Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting GlobeNewswire Inc. - 5/16/2019 4:15:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/1/2019 6:50:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2019 6:49:35 AM
Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 5/1/2019 5:00:00 AM
New Drug Submission Filed for Vascepa® with Health Canada GlobeNewswire Inc. - 4/29/2019 6:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 7:02:14 AM
Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019 GlobeNewswire Inc. - 4/24/2019 6:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/15/2019 5:08:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2019 5:09:07 PM
Vascepa® Granted Priority Review Status from Health Canada GlobeNewswire Inc. - 3/29/2019 5:45:15 PM
Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) t... GlobeNewswire Inc. - 3/28/2019 4:51:57 PM
New Updates to the American Diabetes Association’s® 2019 Standards of Medical Care in Diabetes Incorporate Findings from t... GlobeNewswire Inc. - 3/28/2019 5:00:00 AM
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68... GlobeNewswire Inc. - 3/19/2019 6:00:00 AM
Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Lev... GlobeNewswire Inc. - 3/18/2019 4:15:00 PM
Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™ PR Newswire (US) - 3/18/2019 9:00:00 AM
High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Athero... GlobeNewswire Inc. - 3/16/2019 5:30:00 PM
Investor Expectations to Drive Momentum within Amarin, PulteGroup, LivaNova, Teva Pharmaceutical Industries, Viad, and Activi... GlobeNewswire Inc. - 3/6/2019 8:25:00 AM
Amarin to Present at Cowen’s 39th Annual Health Care Conference GlobeNewswire Inc. - 3/5/2019 6:00:00 AM
Important New Data on Vascepa® (Icosapent Ethyl) from the REDUCE-IT™ Trial to Be Presented Regarding Reduction in Total Is... GlobeNewswire Inc. - 3/4/2019 4:30:00 PM
Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights Business Wire - 3/1/2019 5:00:00 PM
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corp. plc & En... Business Wire - 2/27/2019 2:25:00 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/27/2019 6:39:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/27/2019 6:31:09 AM
Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 2/27/2019 5:00:00 AM
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corp. plc & Encou... Business Wire - 2/26/2019 10:24:00 PM
couldbebetter   Saturday, 01/12/19 09:27:15 AM
Re: ChrisInSF post# 171854
Post # of 192502 
ChrisInSF, I agree with you and Dan. I believe that the best
deal we will get may be $30-$40. What gives me pause that I might
be wrong are comments from HDGabor who believes a 3 digit price is
possible. My hope is that the Pfizer rumour will result in potential
bidders getting into the door, now, rather than waiting. HDGabor has
been consistent in his view that a deal (or whatever outcome) will
most likely be known in the 1st quarter.

Over time as the market(s) for Vascepa expands both in the US and in
foreign countries, the price of Vascepa should decline. For example,
once approved in Canada, the government there will negotiate a lower
price. The same for other countries where the government picks up
the tab. In China, it was suggested in an analyst opinion, that the
retail price might have to go to $1.00 per day to be viable. Not
suggesting that will be the case, but discounting will happen and
any BP making its own internal projections is aware of that. When
I run through the numbers in my own model I do not think BP will
give AMRN the huge valuation that many here expect.

As I go over the lists of potential buyers, and it is fun to speculate,
I think it will be a company with a strong cardiovascular sales/rep
force.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist